Advances in Cancer Drug Targets

Volume 1

by

Atta-ur-Rahman

DOI: 10.2174/97816080547561130101
eISBN: 978-1-60805-474-9, 2013
ISBN: 978-1-60805-601-9
ISSN: 2451-8891 (Print)
ISSN: 2213-9915 (Online)



Indexed in: EBSCO.

Advances in Cancer Drug Targets is an e-book series that brings together recent...[view complete introduction]
US $
Buy Personal eBook
89
Order Library eBook
356
Order Printed Copy
*119
Order PDF + Printed Copy (Special Offer)
*163

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

The PIK3CA Gene as a Mutated Target for Cancer Therapy

- Pp. 3-21 (19)

Sarah Croessmann, Justin Cidado, John P. Gustin, David Cosgrove and Ben Ho Park

Abstract

The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can be exploited as effective drug targets. Small molecule inhibitors and monoclonal antibodies directed against the protein products of these genetic anomalies have led to cancer therapies with high specificity and relatively low toxicity. Our group and others have demonstrated that somatic mutations in the PIK3CA gene occur at high frequency in breast and other cancers. Moreover, the majority of mutations occur at three hotspots, making these ideal targets for therapeutic development. Here we review the literature on PIK3CA mutations in cancer, as well as existing data on p110α inhibitors and inhibitors of downstream effectors for potential use as targeted cancer therapeutics.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science